[Postoperative immunochemotherapy of gastric cancer using levamisole].
The first interim analysis on the results of a randomized controlled trial with or without Levamisole in combination with chemotherapy as an adjunct to surgery for gastric cancer was reported. The study was performed by the cooperation of 21 major hospitals in Japan. Two protocols were investigated. In Protocol A, the efficacy of combining Levamisole with Tegafur was tested and in Protocol B, Levamisole with 5-Fluorouracil. In Protocol A, the combination of Levamisole with Tegafur indicated significant elevation of survival rate in rather advanced patients such as stages III and IV or ps (+), n (+) cases. On the other hand, in Protocol B, no difference was observed between Levamisole (+) group and the control.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage*; D009367:Neoplasm Staging; D011182:Postoperative Care; D013274:Stomach Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007978:Levamisole